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BAckground: Multiple sclerosis (MS) is an unpredictable disease that can have 
physical, psychological, and social impacts, reducing health-related quality of life 
(HRQoL). oBjectives: To compare the HRQoL in patients initiated on delayed-
release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and prior 
approved interferon β -1a/b or glatiramer acetate (ABCRE) therapies. Methods: 
Data were identified from the Adelphi MS Disease Specific Programme, a cross-sec-
tional study of MS patients in five EU countries and the US. Relapsing Remitting MS 
(RRMS) patients were identified, receiving DMF or ABCRE therapies with treatment 
duration greater than 12 months. HRQoL was assessed using the Hamburg Quality of 
Life Questionnaire in MS (HAQUAMS), consisting of five domains (fatigue/thinking, 
mobility of lower limbs, mobility of upper limbs, social function and mood) in which 
higher scores indicate poorer HRQoL. Inverse-probability-weighted regression-
adjustment estimated average treatment effects (ATEs) on the HAQUAMS across 
DMF and ABCRE cohorts, utilizing a propensity score generated from age, gender, 
EDSS score at current treatment initiation, BMI, duration of current treatment, line 
of therapy, time since MS diagnosis, and number of comorbid conditions. results: 
A total of 252 (29 DMF, 223 ABCRE) patients completed the HAQUAMS question-
naire. The overall HAQUAMS score was significantly lower in DMF patients com-
pared to ABCRE patients (ATE= -0.45, p< 0.001, vs. 1.95). Significant differences were 
observed in four of the five subscales, as follows: fatigue/thinking (ATE= -0.47, 
p= 0.001, vs. 1.90), lower limb mobility (ATE= -0.43, p= 0.009, vs. 1.84), social function 
(ATE= -0.54, p< 0.001, vs. 2.05), and mood (ATE= -0.45, p< 0.001, vs. 2.40). The ATE for 
upper limb mobility score was not statistically significant (ATE= -0.15, p= 0.075, vs. 
1.38). conclusions: RRMS patients on DMF had significantly better HRQoL as 
measured by the HAQUAMS, versus RRMS patients on ABCRE therapies.
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oBjectives: Fabry disease is a rare, progressive, X-linked lysosomal storage disor-
der caused by deficiency of α -galactosidase A. Multiple major organs are affected, 
impacting on health-related quality of life (HRQoL). Symptomatic disease requires 
lifelong treatment with intravenous enzyme replacement therapy (ERT; two prod-
ucts available), which has been shown to improve long-term outcomes, delay organ 
damage and improve HRQoL. We present the results of a systematic review of the 
humanistic burden of Fabry disease. Methods: We conducted a systematic search 
of MEDLINE, Embase and congress proceedings to identify studies reporting general 
HRQoL in patients with Fabry disease. results: The search identified 30 relevant 
publications reporting data for ERT-treated and -untreated male and female adult 
and paediatric patients. The majority of studies assessed HRQoL using the 36-item 
Short-Form Health Survey (SF-36; n= 18) and/or 5-dimension European Quality of Life 
instrument (EQ-5D; n= 8). HRQoL was reduced compared with the general population 
(n= 12), and was worse than or similar to other chronic or progressive conditions 
(n= 8); furthermore, HRQoL deteriorated with age (n= 2) and with progressive dis-
ease severity (n= 1). Two clinical trials were identified (one placebo-controlled and 
one open-label) that described HRQoL improvements with ERT (agalsidase alfa). 
There were five analyses of registry data for patients receiving ERT: four studies 
demonstrated sustained HRQoL improvements with up to 5 years of agalsidase 
alfa treatment, and one study reported improvements after 1 and 2 years of agalsi-
dase beta therapy. In two small cohorts, overall HRQoL either improved in all SF-36 
domains after 10 years of ERT (n= 6 patients) or did not significantly decrease over 
7 years of ERT (n= 10 patients). conclusions: Patients with Fabry disease experi-
ence significant impairment in HRQoL, and the limited available data suggest that 
this improved while on ERT. Further studies are required to quantify treatment-
associated HRQoL outcomes.
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oBjectives: To assess the effect of brivaracetam (BRV), a new adjunctive therapy of 
partial-onset seizures (POS), on health-related quality of life (HRQoL). Methods: 
Data from three previously reported Phase III trials of BRV in adults with refrac-
tory POS (NCT00490035; NCT00464269; NCT01261325) were pooled. The QOLIE-31-P 
was collected at randomization and after the 12-week treatment period or early 
termination. The QOLIE-31-P is an epilepsy-specific instrument with seven sub-
scales and a Total score ranging from 0 (worse) to 100 (better HRQoL). Mean change 
from baseline to last observation was compared between BRV and placebo using 
ANCOVA controlling for baseline score. Percentages of meaningfully improved 
patients were calculated using published thresholds. results: There were 422, 
179, 324, and 235 patients in the placebo, BRV 50mg/day, 100mg/day, and 200mg/
day groups respectively. All mean (SD) changes were positive; they were similar for 
placebo and BRV for the Total score (+2.8 [12.7], +3.0 [14.0], +2.4 [14.0], +3.0 [12.1]) 
and most subscale scores. There was a BRV dose response for Energy/Fatigue (lower 
scores), Daily Activities and Seizure Worry (both higher scores). BRV 100mg/day 
showed significantly larger improvements than placebo (+7.3 [24.6] vs +5.0 [23.1]; 
p= 0.044) on the Seizure Worry subscale; this was the only significant result. 43.6%, 
41.7%, and 36.6% of BRV 50mg/day, BRV 100mg/day, 200mg/day patients experienced 
a meaningful improvement in the Total score, respectively; the rate was 38.6% for 
placebo. conclusions: Changes in HRQoL were small and generally comparable 
oBjectives: Multiple sclerosis (MS) is a chronic progressive neurologic disease 
and one of the most common causes of disability among young adults. Although 
the clinical manifestations and symptoms of MS are diverse, disease severity 
is generally measured by ambulation based Expanded Disease Severity Scale 
(EDSS). While EDSS captures well the level of disability due to the involvement of 
lower extremities and urinary bladder, its ability to capture other aspects such 
as fatigue and mental function are poor. The aim of this study was to explore the 
relationship between two patient-based measures, a self-administered EDSS and 
Multiple Sclerosis Impact Scale (MSIS-29), a psychometrically validated instru-
ment measuring the physical (20 items) and psychological (nine items) impact 
of MS. Methods: In total, 553 Finnish persons with MS (PwMS) drawn from the 
membership register of the national patient association completed a postal sur-
vey, including EDSS and MSIS-29. results: PwMS at every (0-9) impairment level 
of the EDSS scale were represented. The mean EDSS score was 4.0, indicating 
moderate disability. The physical impact of MS was strongly related to disease 
severity, with the scores ranging from 3.0 in the mildest disease (EDSS 0) to 76.2 
in the most severe disease (EDSS 8 – 9). The psychological impact increased syn-
chronously with the EDSS score in mild disease (EDSS 0 - 3) and peaked at EDSS 
5, declining thereafter from EDSS 5 to 7. In most severe disability (EDSS 8 – 9) the 
psychological impact of MS was equally high as in EDSS 4. conclusions: The 
subjective physical burden of MS increases steadily with self-assessed disease 
severity, whereas the psychological burden does not go hand in hand with the 
self-assessed severity of the disease.
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oBjectives: The Multiple Sclerosis International Quality of Life (MusiQoL) ques-
tionnaire is a self-administered, measure designed to evaluate the quality of life of 
patients with multiple sclerosis (MS). The MusiQoL was co-developed in 14 coun-
tries. It is composed of 31 items describing nine dimensions (activity of daily living, 
psychological well-being, symptoms, relationships with friends, relationships with 
family, relationships with health care system, sentimental and sexual life, coping, 
and rejection). The objective of this study is to present the challenges faced dur-
ing the translation of the MusiQoL in 57 additional languages representing seven 
language families. Methods: In each country, the translation process (linguistic 
validation) was conducted by a linguistic expert, using either the standard forward/
backward methodology or the adjusted process, including cognitive interviews with 
six patients. The basis for discussion was the concept list developed in collaboration 
with the authors. results: Semantic and cultural issues emerged during the pro-
cess. First, item 6 (had difficulty with your occupational activities: e.g., integration, 
interruption, limitation…?) could not be literally translated in most of the coun-
tries. Patients had difficulties understanding the words “integration, interruption, 
limitation.” The periphrasis and examples suggested in the concept list had to be 
used in most cases. Examples of solutions will be provided. Second, activities (e.g., 
shopping, going out to a movie, Do-It-Yourself, gardening) described in the original 
had to be adapted to the religious and social context of the target countries. For 
instance, “going out to a movie” had to be replaced by “going to an amusement park” 
in Saudi Arabia, since cinemas are forbidden for religious reasons. Other examples 
will be presented. conclusions: The initial simultaneous development of the 
MusiQoL in 14 countries minimized the challenges faced during the translation in 
57 additional languages. The collaboration with the developers and the patients’ 
interviews helped to solve the major issues.
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BAckground: Th EuroQol dimension (EQ-5D) is a widely used, standardised, qual-
ity of life measure producing health profildes, indices and states. oBjectives: 
To assess how people with Multiple Sclerosis (MS) on delayed-release dimethyl 
fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon 
β -1a/b or glatiramer acetate (ABCRE) therapies rate their quality of life, based 
on responses to the EQ-5D. Methods: Data were identified from the Adelphi 
MS Disease Specific Programme, a cross-sectional study of MS patients in five 
EU countries and the US. Relapsing Remitting MS (RRMS) patients were identi-
fied, receiving DMF or ABCRE therapies with treatment duration greater than 12 
months. General HRQoL was evaluated using the EQ-5D 3 level utility score, a 
standardized instrument providing a simple, generic measure of health, consisting 
of 5 questions measuring dimensions of health states (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression). A visual analog scale (VAS) is 
also included to measure overall health. Inverse-probability-weighted regression-
adjustment estimated average treatment effects (ATEs) on the EQ-5D across DMF 
and ABCRE cohorts, utilizing a propensity score generated from age, gender, EDSS 
score at current treatment initiation, BMI, duration of current treatment, line of 
therapy, time since MS diagnosis, and number of comorbid conditions. results: 
A total of 258 (30 DMF, 228 ABCRE) patients completed the EQ-5D questionnaire 
(mean age, 37.4 years; 31% male) with a mean time since diagnosis of 5.57 years. 
There was a significant difference in the EQ-5D utility score between the DMF and 
ABCRE cohorts (ATE: +0.075, p= 0.016, vs. 0.82 for ABCRE). Similarly, the overall VAS 
health reported by patients in the DMF cohort was significantly higher than the 
ABCRE cohort (ATE: +10.84, p< 0.001, vs 74.55 for ABCRE). conclusions: Patients 
on DMF reported significantly better functioning and quality of life compared with 
ABCRE patients, as measured by the EQ-5D.
